Skip to content

Released Nov 14, 2019, after the close

10-Q filed Nov 14, 2019, 45 days after period end · 0001390478-19-000056

Q3 2019 · 10-Q
Revenue—
Net Income-$4.20MN/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$2.68N/M vs Q3 2018N/M vs Q2 2019
Operating Cash Flowderived-$3,820,000N/M

What the release said

The release

Same quarter

MetricQ3 2019Q3 2018Q3 2017Q3 2016
Net Income-$4.20M-$290.00K-$4.46M-$6.93M
EPS Diluted-$2.68-$26.75-$2.27—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR